Literature DB >> 31705198

Developments in oligometastatic hormone-sensitive prostate cancer.

Phuoc T Tran1, Piet Ost2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31705198     DOI： 10.1007/s00345-019-03009-w

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  21 in total

1.  Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.

Authors:  Luca Triggiani; Rosario Mazzola; Stefano Maria Magrini; Gianluca Ingrosso; Paolo Borghetti; Fabio Trippa; Andrea Lancia; Beatrice Detti; Giulio Francolini; Fabio Matrone; Roberto Bortolus; Giuseppe Fanetti; Ernesto Maranzano; Francesco Pasqualetti; Fabiola Paiar; Marco Lorenzo Bonù; Alessandro Magli; Alessio Bruni; Ercole Mazzeo; Ciro Franzese; Marta Scorsetti; Filippo Alongi; Barbara Alicja Jereczek-Fossa; Piet Ost; Michela Buglione
Journal:  World J Urol       Date:  2019-03-11       Impact factor: 4.226

2.  Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Authors:  C Leigh Moyer; Ryan Phillips; Matthew P Deek; Noura Radwan; Ashley E Ross; Emmanuel S Antonarakis; Diane Reyes; Jean Wright; Stephanie A Terezakis; Daniel Y Song; Curtiland DeVille; Patrick C Walsh; Theodore L DeWeese; Michael Carducci; Edward M Schaeffer; Kenneth J Pienta; Mario Eisenberger; Phuoc T Tran
Journal:  World J Urol       Date:  2018-09-06       Impact factor: 4.226

Review 3.  The oligometastatic state - separating truth from wishful thinking.

Authors:  David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

4.  Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer.

Authors:  Sarah Buelens; Elise De Bleser; Bert Dhondt; Wesley Verla; Karel Decaestecker; Piet Ost; Valérie Fonteyne; Kathia De Man; Chloë Standaert; Sylvie Rottey; Nicolaas Lumen
Journal:  World J Urol       Date:  2018-08-22       Impact factor: 4.226

5.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

Review 6.  Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.

Authors:  Andrei Fodor; Andrea Lancia; Francesco Ceci; Maria Picchio; Morten Hoyer; Barbara Alicja Jereczek-Fossa; Piet Ost; Paolo Castellucci; Elena Incerti; Nadia Di Muzio; Gianluca Ingrosso
Journal:  World J Urol       Date:  2018-05-11       Impact factor: 4.226

7.  Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Authors:  M T Schweizer; X C Zhou; H Wang; T Yang; F Shaukat; A W Partin; M A Eisenberger; E S Antonarakis
Journal:  Ann Oncol       Date:  2013-08-14       Impact factor: 32.976

8.  MicroRNA expression characterizes oligometastasis(es).

Authors:  Yves A Lussier; H Rosie Xing; Joseph K Salama; Nikolai N Khodarev; Yong Huang; Qingbei Zhang; Sajid A Khan; Xinan Yang; Michael D Hasselle; Thomas E Darga; Renuka Malik; Hanli Fan; Samantha Perakis; Matthew Filippo; Kimberly Corbin; Younghee Lee; Mitchell C Posner; Steven J Chmura; Samuel Hellman; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2011-12-13       Impact factor: 3.240

9.  microRNAs and oligometastasis.

Authors:  Nikolai N Khodarev; Sean P Pitroda; Ralph R Weichselbaum
Journal:  Aging (Albany NY)       Date:  2015-03       Impact factor: 5.682

10.  Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion.

Authors:  Phuoc T Tran; Emmanuel S Antonarakis
Journal:  J Oncol Pract       Date:  2017-01-03       Impact factor: 3.840
View more
  1 in total

1.  Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.

Authors:  Henan Zhang; Jacob J Orme; Haidong Dong; Sean S Park; Feven Abraha; B J Stish; Val J Lowe; Fabrice Lucien; Erik J Tryggestad; Michael S Bold; Lance C Pagliaro; C Richard Choo; Debra H Brinkmann; Matthew J Iott; Brian J Davis; J Fernando Quevedo; William S Harmsen; Brian A Costello; Geoffrey B Johnson; Mark A Nathan; Kenneth R Olivier; Thomas M Pisansky; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2021-09-30       Impact factor: 13.801
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.